PQB Stock Overview

A biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. More details

PQB fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Makes less than USD$1m in revenue (PLN-11M)

Earnings have declined by 36.8% per year over past 5 years

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the German market

+ 3 more risks

My Notes

Capture your thoughts, links and company narrative

Pure Biologics S.A. Competitors

Medigene

XTRA:MDG1

€15.1m

co.don

XTRA:CNW

€6.5m

4SC

DB:VSC

€59.1m

bioXXmed

XTRA:T5O

€649.9k

Price History & Performance

Summary of share price highs, lows and changes for Pure Biologics
Historical stock prices
Current Share Price	zł3.73
52 Week High	zł6.77
52 Week Low	zł1.25
Beta	1.47
1 Month Change	2.47%
3 Month Change	-14.65%
1 Year Change	42.64%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	119.41%

Recent updates

Shareholder Returns

	PQB	DE Biotechs	DE Market
7D	0.9%	2.5%	-0.4%
1Y	42.6%	-10.2%	7.9%

Return vs Industry: PQB exceeded the German Biotechs industry which returned -10.2% over the past year.

Return vs Market: PQB exceeded the German Market which returned 7.9% over the past year.

Price Volatility

Is PQB's price volatile compared to industry and market?
PQB volatility
PQB Average Weekly Movement	13.7%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: PQB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: PQB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2010	4	n/a	purebiologics.com

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.

Pure Biologics S.A. Fundamentals Summary

How do Pure Biologics's earnings and revenue compare to its market cap?
PQB fundamental statistics
Market cap	€14.89m
Earnings (TTM)	-€10.47m
Revenue (TTM)	n/a

-6.0x

P/S Ratio

-1.4x

P/E Ratio

Is PQB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PQB income statement (TTM)
Revenue	-zł10.52m
Cost of Revenue	zł2.67m
Gross Profit	-zł13.19m
Other Expenses	zł31.51m
Earnings	-zł44.70m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-11.92
Gross Margin	125.36%
Net Profit Margin	424.91%
Debt/Equity Ratio	-273.6%

How did PQB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 08:35
End of Day Share Price	2025/01/03 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pure Biologics S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Sylwia Jaskiewicz	Dom Maklerski Banku Ochrony Srodowiska S.A.

Pure Biologics DB:PQB Stock Report